BUSINESS

Xofluza Filed in US to Treat Patients at High Risk of Flu-Related Complications: Shionogi

March 7, 2019

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Shionogi said on March 6 that the US FDA has accepted a supplemental new drug application (sNDA) for Xofluza (baloxavir marboxil) for the treatment of influenza in patients at a high risk of influenza-related complications aged 12 or older.The submission…

To read the full story

FDA OKs Xofluza for Flu Patients Carrying High Complication Risks
October 21, 2019

BUSINESS

Hisamitsu Starts Promotion of Yaz AGs under Bayer Alliance
March 11, 2026
Seagen ADC Patent Dispute Ends with Daiichi Sankyo Victory
March 11, 2026
Seikagaku Re-Files Herniated Disk Drug with US FDA
March 11, 2026
Lotte to Step Up CVC Investments to Drive CDMO Synergies
March 10, 2026
Ipsen to Withdraw Tazverik Overseas over Secondary Cancer Risk
March 10, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Elevidys Opens New Era for DMD Treatments Targeting the Underlying Cause

By Shinya Sato

Chugai Pharmaceutical’s Duchenne muscular dystrophy (DMD) gene therapy Elevidys has finally reached the Japanese market after months of safety reviews…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…